Guardion Health Sciences, Inc. (NASDAQ:GHSI – Get Rating) major shareholder Bradley Louis Radoff bought 84,821 shares of the company’s stock in a transaction that occurred on Monday, January 9th. The shares were bought at an average price of $6.88 per share, with a total value of $583,568.48. Following the completion of the acquisition, the insider now directly owns 186,000 shares in the company, valued at $1,279,680. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Guardion Health Sciences Price Performance
Shares of GHSI stock opened at $7.23 on Thursday. The stock has a market capitalization of $8.91 million, a PE ratio of -9.90 and a beta of 0.89. Guardion Health Sciences, Inc. has a 1-year low of $5.80 and a 1-year high of $33.09. The business has a 50-day moving average of $0.58 and a 200 day moving average of $0.30.
Guardion Health Sciences (NASDAQ:GHSI – Get Rating) last released its quarterly earnings results on Monday, November 14th. The company reported ($0.03) EPS for the quarter. The business had revenue of $2.66 million for the quarter. Guardion Health Sciences had a negative net margin of 187.52% and a negative return on equity of 32.56%.
Institutional Inflows and Outflows
Guardion Health Sciences Company Profile
Guardion Health Sciences, Inc, together with its subsidiaries, operates as a specialty health sciences company in the United States. It operates in two segments, Medical Foods and Nutraceuticals, and Medical Devices. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma.
Further Reading
- Get a free copy of the StockNews.com research report on Guardion Health Sciences (GHSI)
- Bloom Energy Powers Up After an Upgrade, is it Worth the Risk?
- Why Hershey Is a Sweet Recession Stock
- Will Amazon Stock Be Delivering for Investors in 2023?
- The Analysts Shift Trucking Sentiment Back into Forward
- The Institutions Book A Flight With Boeing
Receive News & Ratings for Guardion Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardion Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.